Biosimilars, Interchangeability, and Perceptions of Safety

Molly Burich, MS; Ha Kung Wong, JD; and Angus Worthing, MD, FACR, FACP, comment on interchangeability as biosimilars enter the rheumatology market in the United States, and remark on perceptions of efficacy and safety of an interchangeable biosimilar versus a biosimilar.
November 06, 2017
View Text Version
x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.